Stanford

Brandon Bergsneider

MD Student with Scholarly Concentration in Informatics & Data-Driven Medicine / Immunology, expected graduation Spring 2026

Bio

BIO

Brandon Hwa-Lin Bergsneider, from Los Angeles, CA, is pursuing an MD at Stanford School of Medicine. Brandon earned a bachelor of science in human biology from Stanford, and a MSc in bioinformatics and theoretical systems biology from Imperial College London. Brandon aspires to use data science-based technologies to advance health equity through early diagnosis, democratizing health information, and improving treatment efficacy. At Stanford and Imperial, he researched the molecular bases of neurodegeneration, the genetic susceptibility of neuroblastoma patients to SARS-CoV-2, computational protein structure prediction, and using machine learning to identify chemotherapy-resistant cancer cells. Brandon has also worked at the National Institutes of Health, where he used computational network analysis to identify clinical and demographic determinants of brain tumor patient symptom burden. Brandon has multiple first-author publications and, outside of academics, enjoys volunteering as a surf-therapy instructor for military veterans. He is a Knight-Hennessy Scholar, a Fulbright Scholar, and an NIH Cancer Research Training Award Fellow.

Publications

PUBLICATIONS

- **Cross-species transcriptomic integration reveals a MIRO1-mediated macrophage-T cell axis in glioma.** *Life science alliance*
  Du, Z., Li, M., Bergsneider, B. H., Tsai, A. P., Cho, K. B., Kim, L. H., Choi, J., Li, G., Wyss-Coray, T., Lim, M., Wang, X.
  2026; 9 (8)
- **Biomarkers for predicting immunotherapy response and resistance in glioblastoma.** *Frontiers in immunology*
  Kim, S., Abikenari, M., Bergsneider, B., Kim, L. H., Lim, M.
  2026; 17: 1823338
- **Precision Immunotherapeutics for Glioblastoma: Current Approaches and Emerging Strategies in 2026.** *Cells*
  Poe, J., Kim, C., Coleman, C., Nguyen, H., Velazhahan, V., Bergsneider, B., Sanker, V., Kim, S., Chen, Y., Abikenari, M., Choi, J., Lim, M.
  2026; 15 (6)
- **Nexus of IDO1/Kynurenine Pathway to T-Cell Exhaustion: Hypoxia-Induced Tryptophan Metabolism in Glioblastoma.** *Metabolites*
  Abikenari, M., Nageeb, G., Ha, J. H., Sjoholm, M. A., Liu, J., Bergsneider, B., Valenzuela, J., Poe, J., Bog Cho, K., Verma, R., Wu, C., Sanker, V., Medikonda, et al
  2026; 16 (3)
- **Adaptive immunotherapeutic paradigms in diffuse midline glioma: integrating epigenetic reprogramming, neuron-glioma interactions, and tumor microenvironment modulation.** *Journal of neuro-oncology*
  Liu, J., Ha, J. H., Abikenari, M., Sjoholm, M. A., Annagiri, S., Ravi, K., Bergsneider, B. H., Verma, R., Theodros, D., Medikonda, R., Li, G., Prolo, L. M., Monje, et al
  2025; 176 (2): 144
- **Spatially Encoded Oncogenesis and Transcriptional Plasticity in Meningioma: Drivers of Therapeutic Resistance and Opportunities for Targeted Intervention.** *Cancers*

Abikenari, M. A., Regev, A., Bergsneider, B. H., Himic, V., Annagiri, S., Kim, L. H., Medikonda, R., Choi, J., Jeyaretna, S., Fountain, D. M., Lim, M.
2025; 17 (16)

- **Distinct myeloid-derived suppressor cell populations in human glioblastoma.** *Science (New York, N.Y.)*
  Jackson, C., Cherry, C., Bom, S., Dykema, A. G., Wang, R., Thompson, E., Zhang, M., Li, R., Ji, Z., Hou, W., Zhan, W., Zhang, H., Choi, et al
  2025; 387 (6731): eabm5214

- **PRONA: An R-package for Patient Reported Outcomes Network Analysis.** *Bioinformatics (Oxford, England)*
  Bergsneider, B. H., Celiku, O.
  2024

- **Symptom Network Analysis and Unsupervised Clustering of Oncology Patients Identifies Drivers of Symptom Burden and Patient Subgroups With Distinct Symptom Patterns.** *Cancer medicine*
  Bergsneider, B. H., Armstrong, T. S., Conley, Y. P., Cooper, B., Hammer, M., Levine, J. D., Paul, S., Miaskowski, C., Celiku, O.
  2024; 13 (19): e70278

- **The CCR6-CCL20 axis promotes regulatory T cell glycolysis and immunosuppression in tumors.** *Cancer immunology research*
  Pant, A., Jain, A., Chen, Y., Patel, K., Saleh, L., Tzeng, S., Nitta, R. T., Zhao, L., Wu, C. Y., Bederson, M., Wang, W. L., Bergsneider, B. H., Choi, et al
  2024

- **The cytokine Meteorin-like inhibits anti-tumor CD8+ T cell responses by disrupting mitochondrial function.** *Immunity*
  Jackson, C. M., Pant, A., Dinalankara, W., Choi, J., Jain, A., Nitta, R., Yazigi, E., Saleh, L., Zhao, L., Nirschl, T. R., Kochel, C. M., Hwa-Lin Bergsneider, B., Routkevitch, et al
  2024

- **CCR2 and CCR5 co-inhibition modulates immunosuppressive myeloid milieu in glioma and synergizes with anti-PD-1 therapy.** *Oncoimmunology*
  Pant, A., Hwa-Lin Bergsneider, B., Srivastava, S., Kim, T., Jain, A., Bom, S., Shah, P., Kannapadi, N., Patel, K., Choi, J., Cho, K. B., Verma, R., Yu-Ju Wu, et al
  2024; 13 (1): 2338965

- **Discovery of clinical and demographic determinants of symptom burden in primary brain tumor patients using network analysis and unsupervised clustering.** *Neuro-oncology advances*
  Bergsneider, B. H., Vera, E., Gal, O., Christ, A., King, A. L., Acquaye, A., Choi, A., Leeper, H. E., Mendoza, T., Boris, L., Burton, E., Lollo, N., Panzer, et al
  2023; 5 (1): vdac188

- **Analysis of SARS-CoV-2 infection associated cell entry proteins ACE2, CD147, PPIA, and PPIB in datasets from non SARS-CoV-2 infected neuroblastoma patients, as potential prognostic and infection biomarkers in neuroblastoma.** *Biochemistry and biophysics reports*
  Bergsneider, B., Bailey, E., Ahmed, Y., Gogineni, N., Huntley, D., Montano, X.
  2021; 27: 101081

- **Next-Generation Sequencing and Personalized Medicine for Brain Cancer** *CURRENT SURGERY REPORTS*
  Bergsneider, B. H., Liau, L. M.
  2018; 6 (12)